HIGHLIGHTS
SUMMARY
Therapy to inhibit the renin-angiotensin system (RAS) is effective and well-tolerated in diabetic and nondiabetic patients with heart failure, regardless of the clinical findings. To date, no evidence has demonstrated the role of hyperglycemia on the expression of GlycACE2 in cardiomyocytes of human beating diabetic hearts, which could impact the binding of Ang-I and Ang-II and, consequently, the expression levels of Ang 1-9 and Ang 1-7 in humans. The authors investigated whether changes in the GlycACE2 levels affect the anti-remodeling molecular pathways of the RAS inhibition, evaluating . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.